Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006509 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00006509 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 12 participants.
The verdict
NCT00006509, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to see if 2 study vaccines, ALVAC-HIV (vCP1452) and gp160 MN/LAI-2, are safe and effective in boosting the body's attacks on HIV in HIV-positive patients. HIV-infected patients who have been treated with anti-HIV drugs for a long time may have weakened immune responses. One way to strengthen these responses may be to have a safe and effective vaccine, which will boost immune responses that are specific to HIV.
Interventions
- BIOLOGICAL ALVAC(2)120(B,MN)GNP (vCP1452)
- BIOLOGICAL gp160 MN/LAI-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006509
The ClinicalTrials.gov registry entry for NCT00006509 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ALVAC(2)120(B,MN)GNP (vCP1452) is the first listed.
NCT00006509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006509 about?
NCT00006509 is a clinical study titled "A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years". The purpose of this study is to see if 2 study vaccines, ALVAC-HIV (vCP1452) and gp160 MN/LAI-2, are safe and effective in boosting the body's attacks on HIV in HIV-positive patients. HIV-infected patients who have been treated with anti-HIV drugs for a long time may have weakened immune responses....
What is the current status of trial NCT00006509?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00006509?
The interventions under investigation include: ALVAC(2)120(B,MN)GNP (vCP1452) (BIOLOGICAL), gp160 MN/LAI-2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006509?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.